A Systematic Review and Meta-Analysis on the Number of Adjuvant Temozolomide Cycles in Newly Diagnosed Glioblastoma
| Autor: | Seyed Alireza Javadinia, Farzad Taghizadeh-Hesary, Pejman Porouhan, Danial Fazilat-Panah, Fahimeh Attarian, Azar Fanipakdel, Babak PeyroShabany |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment The Stupp protocol Newly diagnosed temozolomide law.invention extended chemotherapy Randomized controlled trial adjuvant law Internal medicine Medicine RC254-282 Chemotherapy Temozolomide treatment duration business.industry glioblastoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Regimen Meta-analysis Systematic Review business Adjuvant high-grade gliomas Glioblastoma medicine.drug |
| Zdroj: | Frontiers in Oncology, Vol 11 (2021) Frontiers in Oncology |
| DOI: | 10.3389/fonc.2021.779491/full |
| Popis: | BackgroundIn newly diagnosed glioblastoma, radiation with concurrent and adjuvant (six cycles) temozolomide (TMZ) is the established standard of postsurgical care. However, the benefit of extending adjuvant TMZ therapy beyond six cycles has remained unknown.MethodsWe searched PubMed, Web of Science, Scopus, and Embase up to October 1, 2021. The search keywords were “glioblastoma,” “adjuvant chemotherapy,” and their synonyms. The data of randomized clinical trials were extracted and included in this meta-analysis if they had reported patients’ median overall survival (OS) or median progression-free survival (PFS). The standard and extended chemotherapy regimens were considered as adjuvant TMZ up to six cycles and beyond six cycles (up to a total of 12 cycles), respectively. The median OS and median PFS were pooled and compared.ResultsFour studies consisting of 882 patients (461 patients for the standard chemotherapy group and 421 patients for the extended chemotherapy group) were included in this meta-analysis. The extended TMZ regimen was associated with a nonsignificant improvement in PFS [12.0 months (95% CI 9.0 to 15.0) vs. 10.0 months (95% CI 7.0 to 12.0), P = 0.27] without corresponding improvement in OS [23.0 months (95% CI 19.0 to 27.0) and 24.0 months (95% CI 20.0 to 28.0), P = 0.73].ConclusionsIn newly diagnosed glioblastoma, continuing adjuvant TMZ beyond six cycles did not shown an increase neither in PFS nor OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|